| Predictive Factors for Response to Lutetium-177 PSMA Radioligand Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer NCT07863986 Lithuanian University of Health Sciences | Recruiting | — | August 4, 2026 |
| 177Lu-PSMA-617 Combined With Darolutamide in Neoadjuvant Treatment of High-risk Localized Prostate Cancer: a Prospective, Single-arm, Multi-center Clinical Trial NCT07677566 The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Not yet recruiting | Phase 4 | July 1, 2026 |
| A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan NCT07677267 Novartis Pharmaceuticals | Recruiting | — | June 30, 2026 |
| 68Ga-PSMA-11 PET-directed Radioligand Therapy in Metastatic Hepatocellular Carcinoma (HCC) NCT06852820 Melissa Lumish | Recruiting | Phase 2 | Jun 2026 |
| Lu-177 PSMA Treatment in Cell Renal Carcinoma NCT06959433 Ankara University | Not yet recruiting | Phase 3 | May 1, 2026 |
| Radiopharmaceutical Treatment of Advanced Kidney Cancer NCT06783348 European Organisation for Research and Treatment of Cancer - EORTC | Recruiting | Phase 2 | April 7, 2026 |
| Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial NCT07200830 Alliance for Clinical Trials in Oncology | Recruiting | Phase 3 | March 31, 2026 |
| 177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer NCT07145177 University of California, San Francisco | Recruiting | Phase 1 | March 16, 2026 |
| 177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer NCT07219147 City of Hope Medical Center | Recruiting | Phase 1 | March 6, 2026 |
| Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma NCT07150715 Jonsson Comprehensive Cancer Center | Recruiting | Phase 2 | December 12, 2025 |
| A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC NCT07226986 Novartis Pharmaceuticals | Recruiting | Phase 1, Phase 2 | December 5, 2025 |
| Prostate Cancer Burden and Heterogeneity Evaluation Towards Liquid Biopsy: a Correlation Study to 18FDCFPyL PET and Patients Outcome NCT06917781 Institut Claudius Regaud | Recruiting | N/A | October 28, 2025 |
| A Study of 177Lu-PSMA-617 in People With Gliomas NCT07223034 Memorial Sloan Kettering Cancer Center | Recruiting | Phase 1 | October 27, 2025 |
| An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01) NCT07206056 Novartis Pharmaceuticals | Recruiting | Phase 1, Phase 2 | October 15, 2025 |
| An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC NCT06894511 Novartis Pharmaceuticals | Active, not recruiting | Phase 2 | September 11, 2025 |
| Personalized vs. Fixed-Activity 177Lu-PSMA-617 Radiopharmaceutical Therapy (PRODIGY-2) NCT06943495 Jean-Mathieu Beauregard | Recruiting | Phase 1 | August 15, 2025 |
| 177LuPSMA in Renal Cell Carcinoma NCT06964958 Dana-Farber Cancer Institute | Active, not recruiting | Phase 2 | July 31, 2025 |
| Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer NCT06738303 Case Comprehensive Cancer Center | Recruiting | Phase 2 | July 14, 2025 |
| Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617 NCT07054346 Thomas Hope | Recruiting | Phase 1 | July 8, 2025 |
| A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) NCT07047118 Novartis Pharmaceuticals | Active, not recruiting | Phase 2 | July 3, 2025 |
| Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC NCT06855277 Novartis Pharmaceuticals | Recruiting | Phase 3 | July 1, 2025 |
| Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617 NCT06972628 Ebrahim S Delpassand | Recruiting | Phase 2 | May 23, 2025 |
| STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer NCT06574880 Angela Y. Jia, MD PhD | Recruiting | Phase 1, Phase 2 | May 13, 2025 |
| Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease NCT06526299 University of Washington | Recruiting | Phase 2 | April 29, 2025 |
| Post Marketing Study on Pluvicto in Korea NCT06514521 Novartis Pharmaceuticals | Recruiting | — | April 18, 2025 |
| Study of Re-treatment With [177Lu]Lu-PSMA in Men With Metastatic Castration Resistance Prostate Cancer NCT06866938 Hospices Civils de Lyon | Recruiting | Phase 2 | April 11, 2025 |
| Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy NCT06798558 Hackensack Meridian Health | Recruiting | Phase 2 | March 5, 2025 |
| Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial NCT06632977 Alliance for Clinical Trials in Oncology | Recruiting | Phase 2 | February 6, 2025 |
| SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization NCT06389097 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | — | February 3, 2025 |
| SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy NCT07096999 University of Michigan Rogel Cancer Center | Recruiting | — | January 23, 2025 |
| 177Lu-PSMA as a Systemic Adjuvant Treatment in Patients With High and Very High Risk Prostate Cancer NCT06449781 Maria Sklodowska-Curie National Research Institute of Oncology | Recruiting | Phase 2 | January 9, 2025 |
| 18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer NCT06706921 VA Greater Los Angeles Healthcare System | Recruiting | Phase 4 | December 15, 2024 |
| XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer NCT06568562 University of Utah | Recruiting | Phase 2 | December 9, 2024 |
| Comprehensive Assessment of Cancer Theranostic Response NCT06815354 AIQ Solutions | Active, not recruiting | N/A | December 2, 2024 |
| A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study NCT06531499 Novartis Pharmaceuticals | Active, not recruiting | Phase 1 | November 11, 2024 |
| Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer NCT06145633 Fred Hutchinson Cancer Center | Recruiting | Phase 2 | September 18, 2024 |
| Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders) NCT06496581 UNICANCER | Recruiting | Phase 3 | September 12, 2024 |
| Study of [177Lu]Lu-PSMA-137 In Metastatic Castrate Resistant Prostate Cancer（mCRPC） NCT06546527 Peking University First Hospital | Not yet recruiting | Early phase 1 | August 1, 2024 |
| Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial NCT06288113 Jonsson Comprehensive Cancer Center | Recruiting | Phase 2 | August 1, 2024 |
| Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT) NCT06216249 Jonsson Comprehensive Cancer Center | Recruiting | Phase 2 | August 1, 2024 |